Laboratorios Del Dr. Esteve S.a.

Laboratories Del Dr. Esteve S.a.

Maria Rosa Cuberes-Altisent

Jordi Frigola-Constansa

Joerg Holenz

Alberto Dordal Zueras

Juan Pares-Corominas

Nadine Jagerovic

Jordi Corbera Arjona

Juana Maria Berrocal-Romero

Maria Pilar Goya-Laza

Antoni Torrens Jover

Christian Laggner

Maria Montserrat Contijoch-Llobet

David Vaño-Domenech

Daniel Martínez-Olmo

Jose Maria Cumella-Montanchez

Carmen Almansa-Rosales

Jordi Corbera-Arjona

Jose Luis Diaz-Fernandez

Maria Magdalena Bordas Gelabert

Maria Jose Pretel Sanchez

Cristina Ana Gomez-De La Oliva

Lluis Sola-Carandell

Maria Montserrat-Contijoch-Llobet

Urko Garcia-Couceiro

Pyrazolo[3,4-d]pyrimidine compounds having a great affinity for sigma receptors, especially sigma-1 receptors, as well as a process for preparing these compounds, compositions comprising them and their use as medicaments. The compounds have the following general formula (I): 

[object Object]

The invention relates to compounds having the formula (I): wherein the dashed line (represented by - - - ) represents an optional double bond; Also provided are methods for the preparation of compounds of formula (I); their uses as a medicaments, particularly for the treatment or prophylaxis of a sigma receptor mediated diseases or conditions.

5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors

The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to pyrazole derivatives of formula I and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use therapy and prophylaxis, in particular for the treatment of psychosis or pain.

Substituted pyrazole sigma receptor antagonists

The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula I to processes of preparation of such compounds and to pharmaceutical compositions comprising them.

1,2,4-triazole derivatives as sigma receptor inhibitors

The invention relates to a process for preparing naphthalen-2-yl-pyrazol-3-one intermediates, tautomers, and salts thereof, to novel intermediates, and to the use of the intermediates in the preparation of sigma receptor inhibitors. 

Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors

The invention relates to compounds of formula (I) having pharmacological activity towards the sigma receptor, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which the sigma receptor is involved. 

Sigma receptor inhibitors

The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,3-triazole derivatives of formula (I) and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis or pain. 

1,2,3-triazole derivatives as sigma receptor inhibitors

The invention relates to the use of compounds having pharmacological activity towards the sigma receptor, and more particularly to 1,2,4-triazole derivatives of formula (I) to processes of preparation of such compounds and to pharmaceutical compositions comprising them. 

The invention relates to compounds having pharmacological activity towards the sigma receptor, and more particularly to pyrazole derivatives of formula (I) and to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use therapy and prophylaxis, in particular for the treatment of psychosis or pain. 

The present invention relates to new pyazoline derivatives of formulaand to physiologically acceptable salts thereof, to the method for their preparation and to their application as medicaments.

Pyrazoline derivatives, their preparation and application as medicaments

The present invention relates to a topical ophthalmic composition comprising at least one compound of general formula I ##STR1## in which n may have the values 0 or 1,

Topical ophthalmic composition comprising a

The present invention relates to novel benzimidazole derivatives characterized in that they are of the general formula I, and their therapeutically acceptable salts, ##STR1## in which: R.sub.1 and R.sub.2, which are identical or different, represent a hydrogen or a halogen atom, a lower alkyl radical, a hydroxyl radical, an alkoxy radical, an alkyl carboxylate radical, or an aryl or substituted aryl radical,

Nonsaditive antihistaminics derived from benzimidazoles

The present invention relates to novel compounds derived from benzimidazole, characterized in that they correspond to the formula I, or their therapeutically acceptable salts, ##STR1## in which: R.sub.1 and R.sub.2, equal or different, represent a hydrogen atom, a halogen, a lower alkyl radical, a hydroxy radical, an alkoxy radical, an alkyl carboxylate radical, an aryl or substituted aryl radical,

Derivatives of benzimidazole and their use as antihistamines

The present invention relates to novel derivatives of 1-diphenylmethyl piperazinyl, characterized in that they correspond to the general formula I, and their therapeutically acceptable salts, ##STR1## in which: R.sub.1 and R.sub.2, equal or different, represent a hydrogen atom, a halogen, a lower alkyl radical, a hydroxy radical, an alkoxy radical, an alkyl carboxylate radical, an aryl or substituted aryl radical,

Growing community of inventors

Barcelona, Spain

Maria Rosa Cuberes-Altisent